Literature DB >> 19188389

Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.

Hidekazu Suzuki, Toshihiro Nishizawa, Hiroe Muraoka, Toshifumi Hibi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19188389      PMCID： PMC2663081          DOI： 10.1128/AAC.00049-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  9 in total

1.  Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones.

Authors:  J E Sánchez; N G Sáenz; M R Rincón; I T Martín; E G Sánchez; M J Martínez
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Efficacy and safety of rabeprazole, amoxicillin, and gatifloxacin after treatment failure of initial Helicobacter pylori eradication.

Authors:  Ala I Sharara; Hani F Chaar; Elie Aoun; Heitham Abdul-Baki; George F Araj; Souha S Kanj
Journal:  Helicobacter       Date:  2006-08       Impact factor: 5.753

3.  Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Kumiko Kurabayashi; Tatsuhiro Masaoka; Hiroe Muraoka; Mikiji Mori; Eisuke Iwasaki; Intetsu Kobayashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.

Authors:  Javier P Gisbert; Manuel Castro-Fernández; Fernando Bermejo; Angeles Pérez-Aisa; Julio Ducons; Miguel Fernández-Bermejo; Felipe Bory; Angel Cosme; Luis-Miguel Benito; Laureano López-Rivas; Eloisa Lamas; Manuel Pabón; David Olivares
Journal:  Am J Gastroenterol       Date:  2006-02       Impact factor: 10.864

Review 5.  Helicobacter pylori: present status and future prospects in Japan.

Authors:  Hidekazu Suzuki; Toshifumi Hibi; Barry James Marshall
Journal:  J Gastroenterol       Date:  2007-02-16       Impact factor: 7.527

6.  In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children.

Authors:  Shigeru Fujimura; Seiichi Kato; Kazuie Iinuma; Akira Watanabe
Journal:  J Med Microbiol       Date:  2004-10       Impact factor: 2.472

7.  Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori.

Authors:  R A Moore; B Beckthold; S Wong; A Kureishi; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori.

Authors:  Jacques Tankovic; Christine Lascols; Quentin Sculo; Jean-Claude Petit; Claude-James Soussy
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

9.  Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Izumi Nakagawa; Eisuke Iwasaki; Tatsuhiro Masaoka; Toshifumi Hibi
Journal:  J Gastroenterol Hepatol       Date:  2008-12       Impact factor: 4.029
  9 in total
  25 in total

Review 1.  Helicobacter pylori and gastric cancer.

Authors:  Hidekazu Suzuki; Eisuke Iwasaki; Toshifumi Hibi
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

Review 2.  Second and third line treatment options for Helicobacter pylori eradication.

Authors:  Mingjun Song; Tiing Leong Ang
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

3.  Enhancement of amoxicillin resistance after unsuccessful Helicobacter pylori eradication.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Hitoshi Tsugawa; Hiroe Muraoka; Juntaro Matsuzaki; Kenro Hirata; Fumiaki Ikeda; Masahiko Takahashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-04-12       Impact factor: 5.191

4.  Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Toshihiro Nishizawa; Kenro Hirata; Hitoshi Tsugawa; Yoshimasa Saito; Sawako Okada; Seiichiro Fukuhara; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

5.  Reply to the letter to the editor: H. pylori test-and-treat should not be put off for gastric cancer prevention in East Asia any longer.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  J Gastroenterol       Date:  2018-06       Impact factor: 7.527

Review 6.  Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance.

Authors:  Vasilios Papastergiou; Sotirios D Georgopoulos; Stylianos Karatapanis
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

7.  Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin.

Authors:  Makoto Sasaki; Naotaka Ogasawara; Keiko Utsumi; Naohiko Kawamura; Tskeshi Kamiya; Hiromi Kataoka; Satoshi Tanida; Tsutomu Mizoshita; Kunio Kasugai; Takashi Joh
Journal:  J Clin Biochem Nutr       Date:  2010-06-17       Impact factor: 3.114

8.  High Efficacy of Finafloxacin on Helicobacter pylori Isolates at pH 5.0 Compared with That of Other Fluoroquinolones.

Authors:  Jung Won Lee; Nayoung Kim; Ryoung Hee Nam; Jung Mogg Kim; Jong Youn Park; Sun Min Lee; Joo Sung Kim; Dong Ho Lee; Hyun Chae Jung
Journal:  Antimicrob Agents Chemother       Date:  2015-09-28       Impact factor: 5.191

9.  Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.

Authors:  Kazunari Murakami; Takahisa Furuta; Takashi Ando; Takeshi Nakajima; Yoshikatsu Inui; Tadayuki Oshima; Toshihiko Tomita; Katsuhiro Mabe; Makoto Sasaki; Takanori Suganuma; Hideyuki Nomura; Kiichi Satoh; Shinichiro Hori; Syuuji Inoue; Takeshi Tomokane; Mineo Kudo; Tomoki Inaba; Susumu Take; Toshifumi Ohkusa; Shojiro Yamamoto; Shigeaki Mizuno; Toshiro Kamoshida; Kenji Amagai; Junichi Iwamoto; Jun Miwa; Masaaki Kodama; Tadayoshi Okimoto; Mototsugu Kato; Masahiro Asaka
Journal:  J Gastroenterol       Date:  2013-01-11       Impact factor: 7.527

Review 10.  Attempts to enhance the eradication rate of Helicobacter pylori infection.

Authors:  Chang Seok Bang; Gwang Ho Baik
Journal:  World J Gastroenterol       Date:  2014-05-14       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.